TNFRSF5/CD40
TNFRSF5/CD40 is a tumor necrosis factor receptor family member expressed by B cells, professional antigen-presenting cells, non-immune cells, and tumors[1]. Mechanistically, CD40-CD40L/CD154 engagement regulates humoral and cellular adaptive immunity, including B-cell proliferation, immunoglobulin isotype switching, and germinal center formation[1][2]. CD40 signaling recruits TRAFs and activates NF-κB, with additional involvement of PI3K/AKT, MAPKs, and JAK3/STAT pathways[3]. In inflammatory disease models, CD40 ligation promotes cytokines, chemokines, matrix metalloproteinases, growth factors, adhesion molecules, and procoagulant responses in vascular and immune-associated cells[4][5]. Compared with related pathway forms, CD40 and CD40L both have membrane and soluble forms, and soluble CD40 may bind CD40L and reduce transmembrane CD40 receptor activation[3][6]. For experimental applications, CD40 agonistic antibodies and CD40L-based strategies require receptor clustering or trimerization, while antagonistic approaches target autoimmune disease, allograft rejection, and inflammatory pathology[3][7].
参考文献:
- [1]. Elgueta R, et al. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009 May;229(1):152-72. [Content Brief]
- [2]. Lougaris V, et al. Hyper immunoglobulin M syndrome due to CD40 deficiency: clinical, molecular, and immunological features. Immunol Rev. 2005 Feb;203:48-66. [Content Brief]
- [3]. Tang T, et al. Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint. Pharmacol Ther. 2021 Mar;219:107709. [Content Brief]
- [4]. Chatzigeorgiou A, et al. CD40/CD40L signaling and its implication in health and disease. Biofactors. 2009 Nov-Dec;35(6):474-83. [Content Brief]
- [5]. Schönbeck U, et al. CD40 signaling and plaque instability. Circ Res. 2001 Dec 7;89(12):1092-103. [Content Brief]
- [6]. Lakshman N, et al. Microglia in the spinal cord stem cell niche regulate neural precursor cell proliferation via soluble CD40 in response to myelin basic protein. Stem Cells. 2025 Feb 12;43(2):sxae076. [Content Brief]
- [7]. Richards DM, et al. Concepts for agonistic targeting of CD40 in immuno-oncology. Hum Vaccin Immunother. 2020;16(2):377-387. [Content Brief]
-
TNFRSF5/CD40 関連製品 (118)
関連製品 (118)
-
SLP7111228
0 Images製品番号: HY-120152CAS 番号: 1449765-82-5SLP7111228 is a selective sphingosine kinase 1 (SphK1) inhibitor and anti-inflammatory agent. SLP7111228 selectively inhibits SphK1 and reduces the production of sphingosine-1-phosphate. SLP7111228 decreases lipopolysaccharide-induced TNFα and IL-1β levels. SLP7111228 alleviates obliterative pulmonary arteriopathy, increases cardiac index and decreases total pulmonary vascular resistance index. SLP7111228 can be used in research related to neuroinflammatory diseases and pulmonary hypertension.
-
Carveol (Standard)
0 Images製品番号: HY-W017370RCAS 番号: 99-48-9Carveol (Standard) is the analytical standard of Carveol. This product is intended for research and analytical applications. Carveol is an orally active monoterpenoid alcohol with neuroprotective, antioxidant, anti-inflammatory, anticonvulsant, antidiabetic, hypolipidemic and hepatoprotective activities. Carveol upregulates the expression of Bcl2, downregulates the expression of caspase-3, TNF-α, IL1β and IL6, activates the Nrf2/HO-1 antioxidant signaling pathway, inhibits the RAGE/NF-κB signaling pathway, and suppresses neuroinflammation and neuronal apoptosis. Carveol inhibits α-synuclein aggregation, improves cognitive ability, and inhibits α-amylase activity. Carveol exerts neuroprotective effects in a rat model of Parkinson's disease. Carveol exhibits antidiabetic effects in alloxan-induced diabetic rats. Carveol alleviates PTZ-induced seizures in rats. Carveol can be used in research related to Parkinson's disease, epilepsy, diabetes and ischemic stroke.
-
TLR7/8 agonist 14
0 Images製品番号: HY-179336TLR7/8 agonist 14 is a TLR7 and TLR8 agonist with EC50 values of 0.53 μM and 4.3 μM, respectively. TLR7/8 agonist 14 increases the secretion of the proinflammatory cytokines TNF-α, IL-1β, IL-8 and IFN-γ. TLR7/8 agonist 14 increases cytokine secretion and expression of CD86. LR7/8 agonist 14 can be used for research colorectal carcinoma.
-
TNX-1500
0 Images製品番号: HY-P991921TNX-1500 is a crystallizable fragment-modified anti-CD154 antibody. TNX-1500 contains the hu5c8 fragment antigen-binding (Fab) domain from Ruplizumab (HY-P99315) and an IgG4 Fc region engineered to reduce FcγRIIa binding. TNX-1500 has significantly weaker binding affinity to FcγRI, FcγRIIaH, FcγRIIbF, FcγRIIIaF, and FcγRIIIaV compared to hu5c8 (Kd values: 8.7 nM, 7100 nM, 4900 nM, 8000 nM, 6000 nM respectively). TNX-1500 prolongs nonhuman primate renal allograft survival, prolongs nonhuman primate cardiac allograft survival. TNX-1500 can be used for the research of allograft rejection[1][2].
-
Cot-IN-4
0 Images製品番号: HY-178726CAS 番号: 1984784-10-2Cot-IN-4 (compound 32) is a potent cancer osaka thyroid (COT) kinase inhibitor with an IC50 of 6 nM. Cot-IN-4 inhibits the phosphorylation of ERK (IC50: 60 nM) and inhibits TNFα release (IC50: 60 nM). Cot-IN-4 also inhibits the formation of the pro-inflammatory cytokine IL-1β (IC50: 0.2 μM) in Uric acid (HY-B2130)-stimulated macrophages. Cot-IN-4 can be used for the study of inflammatory diseases.
-
PROTAC IRAK4 degrader-2
0 Images製品番号: HY-135382CAS 番号: 2374122-27-5PROTAC IRAK4 degrader-2 is a PROTAC degrader targeting IRAK4. PROTAC IRAK4 degrader-2 induces proteasome-dependent degradation of IRAK4 by recruiting the VHL E3 ligase. PROTAC IRAK4 degrader-2 inhibits multiple cytokines in peripheral blood mononuclear cells. PROTAC IRAK4 degrader-2 can be used in the research of autoimmune diseases, inflammatory diseases and neoplastic diseases.
-
Tellimagrandin I
0 Images製品番号: HY-N7764CAS 番号: 79786-08-6Tellimagrandin I is a gap junction protein 43 (Cx43) activator, which is a hydrolyzable ellagitannin (ellagitannin) secondary metabolite extractable from various plants. Tellimagrandin I mainly restores gap junction intercellular communication (GJIC) and induces S-phase arrest in tumor cells by upregulating Cx43; activates inflammatory cells to release TNF-α and VEGF to promote angiogenesis in vivo; and protects DNA from damage via antioxidant and metal chelating effects. Tellimagrandin I can be used in research related to human cervical cancer.
-
CX-Se13
0 Images製品番号: HY-187219CX-Se13 is an orally active pulmonary fibrosis inhibitor with anti-inflammatory and antioxidant activities. CX-Se13 regulates the Keap1/Nrf2/HO-1/NQO1, YAP/TAZ-TEAD, NF-κB p65 and TGF-β/Smads signaling pathways. CX-Se13 activates the cellular antioxidant defense system, restores redox balance, alleviates inflammatory responses, reduces collagen deposition, decreases pro-inflammatory cytokine levels and inhibits pathological progression. CX-Se13 can be used in studies related to pulmonary fibrosis.
-
MEDI-5083
0 Images製品番号: HY-P992408MEDI-5083 is an Fc fusion protein that targets CD40 and is a CD40 agonist. MEDI-5083 stimulates CD40 signaling via NF-κB activation. MEDI-5083 upregulates MHCII, CD80, and CD86 expression, induces pro-inflammatory cytokine secretion, and enhances IFN-γ secretion by memory CD8+ T cells. MEDI-5083 can be used for the research of melanoma, colon carcinoma, and advanced solid tumors[1][2].
-
TNF-α-IN-14
0 Images製品番号: HY-160435CAS 番号: 364039-54-3TNF-α-IN-14 is a potent and selective TNFα inhibitor with an IC50 value of 1.1 µM. TNF-α-IN-14 shows antiinflammatory properties (WO2001072735A2; compound 12).
-
Cacospongionolide B
0 Images製品番号: HY-N21818CAS 番号: 172854-76-1Cacospongionolide B is an orally active sesterterpene compound that can be isolated from Fasciospongia cavernosa. Cacospongionolide B is a secreted phospholipase A2 (sPLA2) inhibitor with an IC50 of 4.3 μM. Cacospongionolide B exhibits antibacterial activity. Cacospongionolide B downregulates the expression of iNOS, COX-2 and TNF-α by inhibiting NF-κB nuclear translocation and its DNA binding, and simultaneously selectively and irreversibly inhibits sPLA2 enzymatic activity. Cacospongionolide B can be used in studies related to bacterial infection and adjuvant arthritis.
-
FFP-104
0 Images製品番号: HY-P991554CAS 番号: 2378693-56-0FFP-104 is a humanized IgG4 monoclonal antibody inhibitor targeting TNFRSF5/CD40. VX70 can be used for chronic autoimmune liver diseases research, such as primary biliary cholangitis (PBC).
-
Anti-inflammatory agent 116
0 Images製品番号: HY-184324CAS 番号: 2975573-18-1Anti-inflammatory agent 116 is an anti-inflammatory agent. Anti-inflammatory agent 116 inhibits the abnormal activation of the NF-κB/MAPK signaling pathway. Anti-inflammatory agent 116 binds to the p50 subunit and impairs the DNA-binding ability of the p65-p50 heterodimer. Anti-inflammatory agent 116 inhibits LPS-induced production of NO and MtROS, secretion of IL-1β and TNF-α, expression of iNOS and COX-2, phosphorylation of IKK, IκB, p65, p38, ERK and JNK, as well as nuclear translocation of p65. Anti-inflammatory agent 116 alleviates sepsis-associated acute liver injury in mice. Anti-inflammatory agent 116 can be used for the research of sepsis-associated acute liver injury.
-
Nrf2 activator-27
0 Images製品番号: HY-184690Nrf2 activator-27 is a Nrf2 activator with anti-inflammatory activity. Nrf2 activator-27 increases the expression level of Nrf2, promotes its nuclear translocation, and upregulates the downstream target proteins HO-1 and NQO1. Nrf2 activator-27 reduces the production of NO, TNF-α, IL-1β and IL-6 in LPS-stimulated macrophages. Nrf2 activator-27 can be used for the research of inflammation-related diseases.
-
Abimufloxacin
0 Images製品番号: HY-187837CAS 番号: 1426216-93-4別名: OPS-2071Abimufloxacin (OPS-2071) is a broad-spectrum quinolone antibacterial agent. Abimufloxacin inhibits the supercoiling activity of DNA gyrase, the decatenation activity of topoisomerase IV, the activation and proliferation of T cells, macrophage activity, as well as the production of TNF-α and IFN-γ. Abimufloxacin exhibits activity against enteropathogenic Gram-positive bacteria, Gram-negative bacteria, quinolone-resistant bacteria, and Crohn's disease-associated bacteria (including Clostridioides difficile and Campylobacter jejuni). Abimufloxacin alleviates colonic inflammation in a mouse model of T cell-mediated colitis. Abimufloxacin can be used in research related to diseases such as intestinal infections and Crohn's disease.
-
Maxadilan TFA
0 Images製品番号: HY-P3483AMaxadilan TFA is a specific irreversible PAC1 receptor agonist and a potent vasodilator peptide present in the salivary glands of sand flies. Maxadilan TFA exhibits anti-apoptotic activity in hADSCs. Maxadilan TFA inhibits pro-inflammatory cytokines (TNF-α) and enhances anti-inflammatory mediators (IL-10). Maxadilan TFA can activate leukocytes and inhibit vascular permeability through PAC1 receptors. Maxadilan TFA promotes neural differentiation of human adipose-derived stem cells. Maxadilan TFA can be used to study endotoxin shock, atherosclerosis, and neurodegenerative diseases[1][2][3][4][5].
-
Semapimod
0 Images製品番号: HY-15509CAS 番号: 352513-83-8別名: CNI-1493 free base; CPSI-2364Semapimod, an inhibitor of proinflammatory cytokine production, can inhibit TNF-α, IL-1β, and IL-6. Semapimod inhibits TLR4 signaling (IC50≈0.3 μM). Semapimod inhibits p38 MAPK and nitric oxide production in macrophages. Semapimod has potential in a variety of inflammatory and autoimmune disorders.
-
Antileishmanial agent-44
0 Images製品番号: HY-184214Antileishmanial agent-44 is a histone deacetylase inhibitor targeting Leishmania donovani Sir2, with an IC50 of 0.652 μM against amastigotes. Antileishmanial agent-44 elevates ROS levels to induce oxidative stress, which causes mitochondrial membrane potential depolarization, cytochrome c release, phosphatidylserine externalization and DNA fragmentation, triggers apoptosis-like cell death, and arrests the cell cycle. Antileishmanial agent-44 upregulates the expression of Th1-type cytokines and NO in macrophages, reshapes host immune responses to eliminate intracellular parasites. Antileishmanial agent-44 inhibits parasites in infected golden hamsters in vivo. Antileishmanial agent-44 can be used for the research of visceral leishmaniasis.
-
Anti-inflammatory agent 11
0 Images製品番号: HY-144727CAS 番号: 63932-07-0Anti-inflammatory agent 11 (compound 16) is a potent antimycobacterial and anti-inflammatory agent. Anti-inflammatory agent 11 inhibits Mtb H37Rv and M299 growth, with MIC50 (minimum inhibitory concentration 50%) of 1.3 and 6.9 μM, respectively. Anti-inflammatory agent 11 inhibits NO through the suppression of iNOS expression, and also inhibited the production of TNF-α and IL-1β. Anti-inflammatory agent 11 can be used for tuberculosis (TB) research.
